I
Ik-Kyung Jang
Researcher at Harvard University
Publications - 427
Citations - 26768
Ik-Kyung Jang is an academic researcher from Harvard University. The author has contributed to research in topics: Myocardial infarction & Intravascular ultrasound. The author has an hindex of 73, co-authored 404 publications receiving 24255 citations. Previous affiliations of Ik-Kyung Jang include Katholieke Universiteit Leuven & Hospital General Universitario Gregorio Marañón.
Papers
More filters
Journal ArticleDOI
Angiographic features of patients with coronary plaque erosion.
Hyung Oh Kim,Chong-Jin Kim,Osamu Kurihara,Vikas Thondapu,Michele Russo,Erika Yamamoto,Tomoyo Sugiyama,Francesco Fracassi,Hang Lee,Taishi Yonetsu,Ik-Kyung Jang,Ik-Kyung Jang +11 more
TL;DR: Patients with NSTE-ACS caused by plaque erosion have less complex angiographic features both at the 3-vessel level and at the culprit lesion level.
Journal ArticleDOI
Spatial Distribution of Vulnerable Plaques: Comprehensive In Vivo Coronary Plaque Mapping
Makoto Araki,Tsunenari Soeda,Hyung Oh Kim,Vikas Thondapu,Michele Russo,Osamu Kurihara,Hiroki Shinohara,Yoshiyasu Minami,Takumi Higuma,Hang Lee,Taishi Yonetsu,Tsunekazu Kakuta,Ik-Kyung Jang +12 more
TL;DR: The present 3-vessel OCT study showed that TCFAs cluster at specific locations in the epicardial coronary arteries, especially in patients with ACS, and was more prevalent in segments with tight stenosis.
Journal ArticleDOI
Tomografía de coherencia óptica: situación actual en el diagnóstico intravascular
TL;DR: La tomografia de coherencia optica parece ser una herramienta de gran utilidad para el cardiologo intervencionista y se la compara with otras tecnicas de diagnostico intravascular.
Journal ArticleDOI
Pharmacologic reperfusion therapy for acute myocardial infarction.
TL;DR: An historical overview of pharmacologic reperfusion therapy for MI is provided, followed by an analysis of current limitations, treatment options, and present and likely future pharmacologic therapies.
Journal ArticleDOI
Effect of body mass index on Argatroban therapy during percutaneous coronary intervention
Marcie J. Hursting,Ik-Kyung Jang +1 more
TL;DR: These findings support the use of actual body weight-adjusted (and ACT-targeted) argatroban therapy during PCI and suggest that dose adjustment for obesity (BMI up to 50.9 kg/m2) is unnecessary.